OBINUTUZUMAB, Zanubrutinib clinical trials

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

This study looks at a new drug, zanubrutinib, combined with obinutuzumab, for people with follicular lymphoma that has come back or not responded to previous treatment. It compares this combination with obinutuzumab alone, to see if the new combination works better.